UK's NuCana Q3 net loss widens, cash runway extends to 2029
NCNA•NuCana's third-quarter net loss widened year over year. The company ended the quarter with £18.3 million in cash and expects its cash resources to fund planned operations into 2029.
1. Quarterly results
NuCana's third-quarter net loss widened year over year. It ended the quarter with £18.3 million in cash and expects its cash resources to fund planned operations into 2029.
2. Drug development
The company completed recruitment for the Phase 2 expansion cohort of NUC-7738 in melanoma and plans to present study results in December 2026. It also said it established a development pathway for NUC-3373 through AI-enabled analysis of proprietary and public datasets.
3. Patent granted
NuCana received a European composition-of-matter patent for NUC-7738. The company aims to complete evaluation of optimal combinations and indications for NUC-3373.
